Trial Profile
An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib (Bay 43-9006) as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma, Assessing Safety and Efficacy.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Feb 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms AUS1
- Sponsors Bayer
- 12 Feb 2020 Status changed from recruiting to completed.
- 30 Aug 2011 New trial record